Panbela's Diverse Pipeline Is Encouraging Amidst Challenges In Pancreatic Cancer Therapy: Analyst
Portfolio Pulse from Vandana Singh
Panbela Therapeutics Inc's (NASDAQ:PBLA) Phase 3 ASPIRE trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has been recommended to continue without modification by the independent Data Safety Monitoring Board (DSMB). The company is also planning a Phase 1 clinical trial for the second quarter of 2023 to evaluate Ivospemin in treating platinum-resistant ovarian cancer. HC Wainwright maintains a Buy rating and a price target of $16 for PBLA.
July 10, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Panbela's Phase 3 ASPIRE trial has been recommended to continue without modification, and a Phase 1 trial for Ivospemin is planned for Q2 2023. HC Wainwright maintains a Buy rating and a price target of $16 for PBLA.
The continuation of the ASPIRE trial and the planned Phase 1 trial for Ivospemin indicate positive progress in Panbela's pipeline. This, coupled with the maintained Buy rating and price target from HC Wainwright, could potentially boost investor confidence and have a positive impact on PBLA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100